Alkem Laboratories (ALKEM) Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
ALKEM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alkem Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,292.00 |
| 52 Week High | ₹6,439.90 |
| 52 Week Low | ₹4,491.65 |
| Beta | 0.34 |
| 1 Month Change | 7.94% |
| 3 Month Change | 9.26% |
| 1 Year Change | -14.75% |
| 3 Year Change | 70.59% |
| 5 Year Change | 84.93% |
| Change since IPO | 283.01% |
Recent News & Updates
Alkem Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 15
Alkem Laboratories (NSE:ALKEM) Has Announced A Dividend Of ₹8.00
Aug 05Recent updates
Alkem Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 15Alkem Laboratories (NSE:ALKEM) Has Announced A Dividend Of ₹8.00
Aug 05Alkem Laboratories' (NSE:ALKEM) Dividend Will Be ₹8.00
Jul 21Alkem Laboratories (NSE:ALKEM) Is Due To Pay A Dividend Of ₹8.00
Jul 07Alkem Laboratories (NSE:ALKEM) Is Due To Pay A Dividend Of ₹8.00
Jun 02Getting In Cheap On Alkem Laboratories Limited (NSE:ALKEM) Is Unlikely
May 19Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Mar 26₹5,396: That's What Analysts Think Alkem Laboratories Limited (NSE:ALKEM) Is Worth After Its Latest Results
Feb 12Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Increased To ₹37.00
Feb 11Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon
Feb 01Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?
Jan 10
Emerging Market Expansion And Tactical US Product Launches To Fuel Significant Growth
Profitability is improving through high-margin product focus, cost control, and strategic U.S. product launches to counter prior market challenges.Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Shareholder Returns
| ALKEM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.4% | -0.8% | 0.1% |
| 1Y | -14.8% | -6.5% | -7.4% |
Return vs Industry: ALKEM underperformed the Indian Pharmaceuticals industry which returned -6.5% over the past year.
Return vs Market: ALKEM underperformed the Indian Market which returned -7.4% over the past year.
Price Volatility
| ALKEM volatility | |
|---|---|
| ALKEM Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 7.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: ALKEM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ALKEM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 18,785 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder.
Alkem Laboratories Limited Fundamentals Summary
| ALKEM fundamental statistics | |
|---|---|
| Market cap | ₹632.74b |
| Earnings (TTM) | ₹22.85b |
| Revenue (TTM) | ₹133.04b |
Is ALKEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKEM income statement (TTM) | |
|---|---|
| Revenue | ₹133.04b |
| Cost of Revenue | ₹50.21b |
| Gross Profit | ₹82.83b |
| Other Expenses | ₹59.99b |
| Earnings | ₹22.85b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 191.07 |
| Gross Margin | 62.26% |
| Net Profit Margin | 17.17% |
| Debt/Equity Ratio | 11.1% |
How did ALKEM perform over the long term?
See historical performance and comparisonDividends
Does ALKEM pay a reliable dividends?
See ALKEM dividend history and benchmarks| Alkem Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Aug 08 2025 |
| Dividend Pay Date | Sep 24 2025 |
| Days until Ex dividend | 27 days |
| Days until Dividend pay date | 20 days |
Does ALKEM pay a reliable dividends?
See ALKEM dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/03 19:10 |
| End of Day Share Price | 2025/09/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkem Laboratories Limited is covered by 36 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |